Potassium Citrate
Potassium citrate is an oral potassium supplement and source of metabolizable alkali. Its principal veterinary applications are selected hypokalemic or acidotic states and reduction of calcium oxalate stone recurrence. In appropriate patients, it provides potassium replacement while increasing citrate availability and modifying the urinary environment.
Group
Potassium supplement and urinary alkalinizer
Mechanism of Action
Potassium citrate supplies potassium, while metabolism of the citrate component generates an alkalinizing effect. Increased urinary citrate binds calcium into more soluble complexes, reducing free calcium available for calcium oxalate crystallization. Changes in urinary pH and citrate handling can also reduce lithogenic conditions. The potassium component separately supports correction of deficient potassium stores.
Dose Rates
Dogs
| Use / stage | Dose | Route | Schedule | Instructions |
|---|---|---|---|---|
| Potassium supplementation | 0.5 mEq/kg | PO | Every 24 h | |
| Calcium oxalate prevention | 50–75 mg/kg | PO | Every 12 h | |
| Urinary alkalinization | 150 mg/kg | PO | Every 24 h | Daily amount mixed with food. |
| Energy-based potassium supplementation | Reference only | PO | 2.2 mEq potassium per 100 kcal/day orally; daily energy intake is required for calculation. | |
| Calcium oxalate prevention | 150 mg/kg | PO | Every 12 h | Studied alternative: urinary calcium oxalate decreased despite little change in urine pH. |
| Calcium oxalate prevention | 40–75 mg/kg | PO | Every 12 h | Avoid over-alkalinization and calcium-phosphate crystallization. |
| Calcium oxalate prevention — Initial | 50 mg/kg | PO | Every 12 h | Titrate using urine pH; target differs by clinical protocol, generally 6.5-7.5. |
| Renal disease-associated potassium and alkali support — Initial | 75 mg/kg | PO | Every 12 h |
Cats
| Use / stage | Dose | Route | Schedule | Instructions |
|---|---|---|---|---|
| Potassium supplementation | 0.5 mEq/kg | PO | Every 24 h | |
| Calcium oxalate prevention | 50–75 mg/kg | PO | Every 12 h | |
| Urinary alkalinization | 150 mg/kg | PO | Every 24 h | Daily amount mixed with food. |
| Potassium supplementation in kidney disease | 1–4 mEq/animal | PO | Every 12 h | Dose expressed as potassium equivalent; titrate to serum results. |
| Energy-based potassium supplementation | Reference only | PO | 2.2 mEq potassium per 100 kcal/day orally; daily energy intake is required for calculation. | |
| Renal disease-associated potassium and alkali support — Initial | 75 mg/kg | PO | Every 12 h | |
| Calcium oxalate prevention — Initial | 50–100 mg/kg | PO | Every 12 h | Reported urine-pH goal approximately 7.5. |
| Calcium oxalate prevention | 100–150 mg/kg | PO | Every 24 h | Effect on urinary citrate is uncertain. |
| Acidemia-associated alkali support | 15–30 mg/kg | PO | Every 12 h | |
| Acidemia-associated alkali support | 2.5 mEq/animal | PO | Every 12 h | Potassium-equivalent alternative, not an asserted exact conversion of the mg/kg range. |
| Hypokalemia in chronic renal disease | 2–4 mEq/animal | PO | Every 24 h |
Indications
- Reduction of recurrent calcium oxalate urolith formation in selected dogs and cats.
- Potassium supplementation in selected hypokalemic patients where alkali supplementation is also appropriate.
- Treatment of selected renal tubular acidosis or other chronic acidotic states requiring oral alkali.
- Combined potassium and alkali support in selected cats with chronic kidney disease, hypokalemia and metabolic acidosis.
Contraindications
- Renal impairment requires caution; avoid supplementation when potassium is excessive.
Interactions
- Other potassium sources, ACE inhibitors and potassium-sparing diuretics can increase hyperkalemia; account for digoxin and diuretic therapy.
Adverse effects
- Gastrointestinal irritation; hyperkalemia causes weakness, bradycardia, arrhythmias and arrest.
Toxicity
Excessive potassium can cause fatal cardiovascular toxicity. Excess can cause GI irritation, alkalosis and hyperkalemia. Discontinue and monitor acid-base, potassium and renal status; manage according to severity.
Preparations
| Preparation | Form | Strength | Route |
|---|---|---|---|
| Potassium citrate 540 mg (5 mEq potassium) tablet Contains 5 mEq potassium; no automated cross-unit conversion inferred. | Tablet | 540 mg / tablet | PO |
| Potassium citrate 1080 mg (10 mEq potassium) tablet Contains 10 mEq potassium; no automated cross-unit conversion inferred. | Tablet | 1080 mg / tablet | PO |
| Potassium citrate 1620 mg (15 mEq potassium) tablet Contains 15 mEq potassium; no automated cross-unit conversion inferred. | Tablet | 1620 mg / tablet | PO |
| Potrate potassium citrate 540 mg tablet Exact manufacturer not established by the accessible portfolio listing; no equal-dose division assumed. | Tablet | 540 mg / tablet | PO |
| Potrate potassium citrate 1080 mg tablet Exact manufacturer not established by the accessible portfolio listing; no equal-dose division assumed. | Tablet | 1080 mg / tablet | PO |
Monitoring and Administration
Adjust from serial potassium concentrations and renal function; use ECG monitoring when indicated.
Administer citrate with meals.
When urine pH is already above approximately 7-7.5, avoid further alkalinization in calcium-oxalate protocols. Monitor potassium periodically, often monthly, and reduce if hyperkalemia develops. Scoop-based granule instructions require the exact product scoop content.